The niacin challenge test in schizophrenia: Past, present and future

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 55, Issue 1-2, 1996, Pages 17-19

  Lin, A ^a   Hudson, C J ^a  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINIC ACID;

CONFERENCE PAPER; HUMAN; MANIC DEPRESSIVE PSYCHOSIS; PHOSPHOLIPID METABOLISM; PRIORITY JOURNAL; PROVOCATION TEST; SCHIZOPHRENIA; TECHNIQUE; VASODILATATION;

EID: 0029777377     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-3278(96)90140-4     Document Type: Conference Paper

References (15)

1. Hudson C., Young L., Li P., Warsh J. J. CNS signal transduction in the pathophysiology and pharmacotherapy of affective disorders and schizophrenia. Synapse 1993; 13: 278-293.
2. Gattaz W. F., Kollisch M., Thuren T., Virtanen J. A., Kinnunen P. K. J. Increased plasma phospholipase-A2 activity in schizophrenic patients: reduction after neuroleptic therapy. Biol Psychiatr 1987; 22: 421-426.
3. Gattaz W. F., Hubner C., Nevalaina T., Thuren T., Kinnunen P. K. J. Increased serum phospholipase-A2 activity in schizophrenia: a replication study. Biol Psychiatr 1990; 28: 495-501.
4. Van Kammen D., Yao J., Goetz K. Polyunsaturated fatty acids, prostaglandins, and schizophrenia. Ann N Y Acad Sci 1989; 559: 411-423.
5. Glen A., Glen E., Horrobin D. et al. A red cell membrane abnormality in a sub-group of schizophrenic patients: evidence for two diseases. Schizophr Res 1994; 12: 53-61.
6. Pettegrew J. W., Keshavan M. S., Panchalingam K. et al. Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics Arch Gen Psychiatr 1991; 48: 563-568.
7. Stanley J. A., Williamson P. C., Drost D. J. et al. An in vivo study of the prefrontal cortex of schizophrenic patients at different stages of illness via phosphorus magnetic resonance spectroscopy. Arch Gen Psychiatr 1995; 52: 399-406.
8. Andersson R. G. G., Aberg G., Brattsand R., Ericsson E., Lundholm L. Studies on the mechanism of flush by nicotinic acid. Acta Pharmacol Toxicol 1977; 41: 1-10.
9. Morrow J., Parsons W., Roberts L. Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid. Prostaglandins 1989; 38: 263-274.
10. Wilkin J., Wilkin O., Kapp R., Donachie R., Chernosky M., Buckner J. Aspirin blocks nicotinic acid-induced flushing. Clin Pharmacol Ther 1982; 31: 478-482.
11. Horrobin D. F. Niacin flushing, prostaglandin E3 and evening primrose oil. A possible objective test for monitoring therapy in schizophrenia. J Orthomolec Psychiatr 1980; 9: 33-34.
12. Wilson D. W. S., Douglass A. B. Niacin skin test is not diagnostic of schizophrenia. Biol Psychiatr 1986; 21: 974-977.
13. Fielder F., Wolkin A., Rostrosen J. Niacin-induced flush as a measure of prostaglandin activity in alcoholics and schizophrenics. Biol Psychiatr 1986; 21: 1347-1350.
14. Rybakowski J., Weterle R. Niacin test in schizophrenia and affective illness. Biol Psychiatr 1991; 29: 834-836.
15. Wilkin J. Chlorpropamide-alcohol flushing, malar thermal circulation index, and baseline malar temperature. Metabolism 1982; 31: 948-954.